Comparison of Symptomatic Vasospasm after Surgical Clipping and Endovascular Coiling

Hirotoshi IMAMURA,1 Shoichi TANI,1 Hidemitsu ADACHI,1 Ryu FUKUMITSU,1 Tadashi SUNOHARA,1 Nobuyuki FUKUI,1 Yoshihiro OMURA,1 Natsuhi SASAKI,1 Tomoaki AKIYAMA,1 Tatsumaru FUKUDA,1 Shinji KAJIURA,1 Masashi SHIGEYASU,1 Kento ASAKURA,1 Ryo HORII,1 and Nobuyuki SAKAI1

1Department of Neurosurgery, Kobe City Medical Center General Hospital, Kobe City, Hyogo, Japan

Abstract

Vasospasm, initial neurological damage, rebleeding, and periprocedural complications are associated with delayed ischemic neurological deficit (DIND) after aneurysmal subarachnoid hemorrhage. In this study, factors related to delayed ischemic neurological deficit (DIND) were evaluated using data from our institute for the last 18 years. Data from 2001 to 2018 of patients with aneurysmal SAH who underwent surgical clipping (SC) or endovascular coiling (EC) within 7 days of onset were retrospectively analyzed. Cases of mortality within 5 days after treatment were excluded. Multivariate analysis was used to identify the risk factors for DIND. In total, 840 cases of SAH were assessed; among these cases, 384 (45.7%) and 456 (54.3%) were treated with SC and EC, respectively. The frequency of DIND in the EC group was significantly less than that in the SC group (11.8% vs. 17.7%; p = 0.016). In the results of multivariate analysis, internal carotid artery (ICA) aneurysm and hemorrhagic complications were risk factors for DIND. Cilostazol administration and EC were significant factors for vasospasm prevention after aneurysmal SAH (odds ratio of ICA aneurysm: 1.59, hemorrhagic complications: 1.76, SC: 1.51, and cilostazol administration: 0.51, respectively). Cilostazol administration was also a significant factor in patients who were treated with EC. ICA aneurysm, treatment strategy, hemorrhagic complications, and cilostazol administration were associated with DIND. Oral administration of cilostazol and avoiding hemorrhagic complications were effective in DIND prevention. If both treatments are available for ruptured aneurysms, clinicians should choose EC on the basis of its ability to prevent DIND.

Keywords: vasospasm, surgical clipping, endovascular coiling, cilostazol

Introduction

Recently, the annual incidence of subarachnoid hemorrhage (SAH) worldwide was 6.67 per 100,000 (range, 0.71-12.38). Despite the low incidence of SAH in patients with stroke, approximately 40% of patients with SAH have poor outcomes, and effective treatment in these patients is a challenge. Important prognostic factors for SAH include impaired consciousness at disease onset, rebleeding, therapeutic complications, and symptomatic vasospasm. Approximately 30%-70% cases of SAH showed symptomatic vasospasm complication that was confirmed via cerebral angiography; approximately 20%-30% of cases with vasospasm were symptomatic, and approximately 15% of those contributed to poor prognosis.

Recent research has focused on the treatment approach in delayed ischemic neurological deficit (DIND), but the results indicated that the effect was limited, and prevention is essential. In this study, we assessed the incidence of DIND and risk factors in patients with SAH who underwent radical intervention at our institute in the past 18 years.

Material and Methods

Patients with SAH who underwent radical treatment for
ruptured intracranial aneurysms within 7 days after onset in our institute between April 2001 and December 2018 were enrolled, and of these patients, 840 who survived more than 5 days after radical treatment were included in the study. The evaluated factors in this study were as follows: patient characteristics (age, gender, medical history [hypertension, diabetes mellitus, dyslipidemia, and SAH], smoking history, and family history of SAH); information on aneurysm (World Federation of Neurological Surgeons (WFNS) grading, Fisher’s grading, presence or absence of intracerebral hematoma and intraventricular hematoma, site of the aneurysms, size, length of the neck, and dome-to-neck ratio); treatment modality (use of cilostazol, statin and eicosapentaenoic acid (EPA), hemorrhagic and non-hemorrhagic complications, and method of radical treatment). Since we hypothesized that hemorrhagic complications would increase vasospasm, hemorrhagic complications included postoperative hemorrhage, contusional hemorrhage, or hemorrhagic infarction. Contrarily, non-hemorrhagic complications were defined as permanent symptomatic events due to cerebral infarction and brain contusion without hematoma. The site of aneurysms was as follows: the anterior cerebral artery, anterior communicating artery, distal internal carotid artery (ICA) (distal to the posterior communicating artery [PcomA]), PcomA, proximal ICA (proximal to PcomA), middle cerebral artery (MCA), basilar artery (BA), and vertebral artery (VA). Additionally, cerebral angiography or brain magnetic resonance angiography was performed to confirm symptomatic vasospasm. DIND was defined as neurological symptoms including new transient or permanent neurological deteriorations with vasospasm in the related territory, except for other causes such as symptomatic epilepsy.

Based on the 2002 report of the International Subarachnoid Aneurysm Trial (ISAT),19 surgeons performing surgical clipping (SC) and endovascular coiling (EC) began negotiations to promote EC as a priority treatment choice in individual patients undergoing radical treatment for ruptured intracranial aneurysms. During this study period, those who were eligible for fasudil hydrochloride were administered with the drug intravenously. After 2010, almost all the patients were administered oral treatment with cilostazol, statin, and EPA. If DIND occurred, patients were administered with Triple-H therapy or hyperdynamic therapy, and in those showing no improvement of symptoms, endovascular treatments were also performed.

In this study, the incidence of DIND since 2001 was evaluated, and a comparison of each factor was done between the SC and EC groups. First, a univariate analysis of factors related to the occurrence of DIND was performed to identify significant factors (p < 0.05). Additionally, a multivariate analysis was performed. Patients were classified by age (>60 and <60 years), WFNS grading (grades 1-3 and 4-5), Fisher’s grading (group 3 and other groups), (>7 and ≤7 mm), and site of the aneurysms (ICA [distal ICA, PcomA, and proximal ICA] and others). The same analysis was also performed for the EC group. All statistical analyses were performed using JMP ver. 10 (SAS Institute Inc.; Cary, NC, USA). Chi-square test, Fisher’s test, and t-test were used for univariate analysis. Multivariate logistic regression analysis was also performed. P-value of <0.05 was considered to be statistically significant.

Results

Choice of treatment

Of the 840 subjects included in the study, radical treatment with SC was performed in 384 patients (45.7%), and that with EC was performed in 456 patients (54.3%). Comparing the temporal changes between the SC and EC groups, the EC group comprised approximately 30% of total patients for 2001, and the incidence was gradually increased in the following years. In 2018 (the final year of the study), EC was performed in approximately 70% of the patients. In the between-group comparison of patient characteristics, a trend of selection of SC for treatment of youths, mild cases, and patients with a history of smoking was observed; many patients in the SC group were diagnosed with small aneurysms, short neck of the aneurysms, MCA aneurysms, or aneurysms with intraventricular hematoma; many patients in the EC group were diagnosed with posterior circulation aneurysms (BA and VA). Regarding factors related to treatment, the following findings were obtained: more frequent administration of cilostazol and EPA in the EC group and a trend of higher incidence of hemorrhagic complications in the EC group than in the SC group (Table 1).

Incidence of DIND

The incidence of DIND was significantly lower in the EC group than in the SC group (11.8% [54/456] vs. 17.7% [68/384]; p = 0.016), whereas the incidence of DIND in the SC group was without significant temporal changes, and that in the EC group decreased gradually, without significance (Fig. 1).

Related factors to DIND

In the univariate analysis of the incidence of DIND, female sex, ICA aneurysms, no use of cilostazol in the treatment, and hemorrhagic complications were significant risk factors other than those described for SC (Table 2). In a subsequent analysis of these factors and other significant factors (p < 0.1) such as diabetes mellitus, ICA aneurysms, hemorrhagic complications, no use of cilostazol in the treatment, and SC were significant risk factors for DIND. The odds ratios of ICA aneurysms and hemorrhagic complications were 1.59 and 1.76, respectively, and those of cilostazol and SC were 0.51 and 1.51, respectively (Table 3). No use of cilostazol was also a significant risk factor for DIND in the EC group (Table 4).
Table 1 Comparison between surgical clipping and endovascular coil embolization

|                                | Surgical clipping group (n = 384) | Endovascular coil embolization group (n = 456) | P-value |
|--------------------------------|----------------------------------|-----------------------------------------------|---------|
| Age (years)                    | 59.8 ± 13.7                      | 63.8 ± 15.1                                   | <0.001* |
| Sex (female)                   | 257 (66.9%)                      | 282 (61.8%)                                   | 0.126   |
| WFNS classification            |                                  |                                               |         |
| Grade 1                        | 122 (31.8%)                      | 99 (21.7%)                                    | <0.001* |
| Grade 2                        | 79 (20.6%)                       | 101 (22.2%)                                   |         |
| Grade 3                        | 22 (5.7%)                        | 4 (0.9%)                                      |         |
| Grade 4                        | 80 (20.8%)                       | 82 (18.0%)                                    |         |
| Grade 5                        | 81 (21.1%)                       | 170 (37.3%)                                   |         |
| Hypertension                   | 187 (48.7%)                      | 217 (47.6%)                                   | 0.748   |
| Diabetes mellitus              | 27 (7.0%)                        | 32 (7.0%)                                     | 0.994   |
| Dyslipidemia                   | 63 (16.4%)                       | 70 (15.4%)                                    | 0.676   |
| Smoking history                | 165 (41.6%)                      | 166 (36.2%)                                   | 0.023*  |
| Family history                 | 29 (19.1%)                       | 34 (17.8%)                                    | 0.761   |
| History of SAH                 | 11 (2.9%)                        | 24 (5.3%)                                     | 0.083   |
| Fisher’s classification        |                                  |                                               |         |
| Group 1                        | 4 (1.0%)                         | 4 (0.9%)                                      | 0.660   |
| Group 2                        | 35 (9.1%)                        | 37 (8.1%)                                     |         |
| Group 3                        | 335 (87.2%)                      | 408 (89.5%)                                   |         |
| Group 4                        | 10 (2.6%)                        | 7 (1.5%)                                      |         |
| Intracerebral hematoma         | 138 (35.9%)                      | 96 (21.1%)                                    | <0.001* |
| Intraventricular hematoma      | 187 (48.7%)                      | 303 (66.5%)                                   | <0.001* |
| Site                           |                                  |                                               |         |
| ACA                            | 39 (10.2%)                       | 25 (5.5%)                                     | <0.001* |
| AcomA                          | 79 (20.6%)                       | 121 (26.5%)                                   |         |
| Distal ICA                     | 17 (4.4%)                        | 28 (6.1%)                                     |         |
| PcomA                          | 63 (16.4%)                       | 108 (23.7%)                                   |         |
| Proximal ICA                   | 15 (3.9%)                        | 20 (4.4%)                                     |         |
| MCA                            | 161 (41.9%)                      | 17 (3.7%)                                     |         |
| BA                             | 6 (1.6%)                         | 56 (12.3%)                                    |         |
| VA                             | 4 (1.0%)                         | 81 (17.8%)                                    |         |
| Size                           | 6.43 ± 3.88                      | 7.63 ± 4.24                                   | <0.001* |
| Length of the neck             | 3.08 ± 1.63                      | 3.66 ± 1.93                                   | <0.001* |
| Dome-to-neck ratio             | 2.16 ± 0.86                      | 2.15 ± 0.83                                   | 0.881   |
| Cilostazol                     | 67 (17.5%)                       | 132 (29.0%)                                   | <0.001* |
| Statin drugs                   | 166 (43.2%)                      | 202 (44.3%)                                   | 0.756   |
| EPA formulations               | 166 (43.2%)                      | 218 (47.8%)                                   | 0.185   |
| Hemorrhagic complications      | 46 (12.0%)                       | 79 (17.3%)                                    | 0.030*  |
| Nonhemorrhagic complications   | 53 (13.8%)                       | 56 (12.3%)                                    | 0.513   |
| DIND                           | 68 (17.7%)                       | 54 (11.8%)                                    | 0.016*  |

*Significant groupwise difference.

WFNS, World Federation of Neurosurgical Societies; SAH, subarachnoid hemorrhage; ACA, anterior communicating artery; AcomA, anterior communicating artery; ICA, internal carotid artery; PcomA, posterior communicating artery; MCA, middle cerebral artery; BA, basilar artery; VA, vertebral artery; EPA, eicosapentaenoic acid; DIND, delayed ischemic neurological deficit.

Discussion

DIND prevention

DIND is usually considered to be a risk factor for complications in patients with the onset of SAH undergoing radical treatment. Nevertheless, no standard guidelines for the prevention and treatment of the disease have been established. The Japanese Guidelines for the Management of Stroke and the American Heart Association (AHA)/the American Stroke Association (ASA) guidelines recommend hypertensive therapy as a treatment approach based on the evidence. Previous studies recommended Triple-H
Fig. 1  Temporal changes in the incidence of delayed ischemic neurological deficit via radical treatment.

Table 2  Factors related significantly to delayed ischemic neurological deficit based on univariate analysis

|                             | With SV (n = 122) | Without SV (n = 718) | P-value |
|-----------------------------|-------------------|----------------------|---------|
| Age (≥60 years)             | 73 (59.8%)        | 391 (54.5%)          | 0.269   |
| Female sex                  | 89 (73.0%)        | 450 (62.7%)          | 0.029*  |
| WFNS classification grades 1-3 | 65 (53.3%)      | 362 (50.4%)          | 0.559   |
| Hypertension                | 543 (43.4%)       | 351 (48.9%)          | 0.266   |
| Diabetes mellitus           | 4 (3.3%)          | 55 (7.7%)            | 0.080   |
| Dyslipidemia                | 16 (13.1%)        | 117 (16.3%)          | 0.374   |
| Smoking history             | 42 (51.9%)        | 289 (57.2%)          | 0.365   |
| Family history              | 9 (20.0%)         | 54 (18.1%)           | 0.762   |
| History of SAH              | 3 (2.5%)          | 32 (4.5%)            | 0.226   |
| Fisher’s classification group 3 | 108 (88.5%)     | 635 (88.4%)          | 0.979   |
| Intracerebral hematoma      | 31 (25.4%)        | 203 (28.3%)          | 0.514   |
| Intraventricular hematoma   | 66 (54.1%)        | 424 (59.1%)          | 0.305   |
| Aneurysm site at the ICA    | 48 (39.3%)        | 203 (28.3%)          | 0.014*  |
| Size                        | 6.50 ± 2.76       | 7.13 ± 4.30          | 0.145   |
| Length of the neck          | 3.26 ± 1.48       | 3.39 ± 1.86          | 0.489   |
| Dome-to-neck ratio          | 2.11 ± 0.76       | 2.16 ± 0.86          | 0.577   |
| Cilostazol                  | 17 (13.9%)        | 182 (25.4%)          | 0.006*  |
| Statin drugs                | 54 (44.3%)        | 314 (43.7%)          | 0.913   |
| EPA formulations            | 54 (44.3%)        | 330 (46.0%)          | 0.728   |
| Hemorrhagic complications   | 26 (21.3%)        | 99 (13.8%)           | 0.031*  |
| Nonhemorrhagic complications| 11 (9.0%)         | 98 (13.7%)           | 0.159   |
| Radical operation type of surgical clipping | 68 (55.7%) | 316 (44.0%) | 0.016* |

*Significant groupwise difference.

SV, symptomatic vasospasm; WFNS, World Federation of Neurosurgical Societies; SAH, subarachnoid hemorrhage; ICA, internal carotid artery; EPA, eicosapentaenoic acid.

therapy but did not confirm their efficacy. Recently, investigators have focused on the selective arterial infusion of a vasodilator such as fasudil hydrochloride and direct percutaneous transluminal angioplasty and reported that the effect was limited. Thus, clinicians should target DIND prevention to achieve improved outcomes of SAH. In this study, we examined factors related to DIND in approximately 850 patients with SAH who underwent surgery at our institute in the past 18 years.
Comparison between EC and SC

Although based on the results of ISAT16 and Barrow Ruptured Aneurysm Trial,17 EC is increasingly considered as the first-line radical treatment for ruptured intracranial aneurysms, studies have reported conflicting results regarding the superiority of SC or EC in terms of the complication rate of DIND.18-20 SC is effective in the removal of the hematoma in the arachnoid space, which may be correlated with the incidence of DIND, whereas EC with minimal invasiveness to the cerebral blood vessels is considered to be effective in DIND prevention. In this study, we observed a significantly lower incidence of DIND in the EC group than in the SC group. Although the incidence of DIND in the SC group showed no temporal changes, the recent incidence of DIND in the EC group tended to decrease, without significance. Advancements in several devices such as intermediate catheters and balloon catheters21-23 have led to significant improvement in treatment outcomes of EC, which may consequently reduce the incidence of DIND.

Risk factors for DIND

Our analysis results revealed specific risk factors for DIND other than the method of radical treatment: ICA aneurysm, hemorrhagic complications, and no oral administration of cilostazol. To our best knowledge, there were no reports of a high rate of DIND complications in the rupture of ICA aneurysms, although studies have reported a correlation between the thickness of intracerebral and intraventricular hematomas and DIND incidences.24-26 Although a recent27 study reported that the aneurism location did not affect the incidence of delayed cerebral infarction, female sex was reported to be an independent predictor of symptomatic vasospasm.28 The present study had a significantly higher frequency of female patients with ICA aneurysms (ICA: 79.3% vs. others: 57.7%), and the high rate of DIND in ICA aneurysms may have been affected by these factors. In this study, we divided all the complications into two groups, namely, hemorrhagic and nonhemorrhagic complications, because we hypothesized that the increase of hematoma could induce vasospasm after radical treatment. Although our results supported this hypothesis, they were inconsistent with the result that Fisher grading did not significantly correlate with DIND. In this study, approximately 90% of the cases were classified as Fisher’s group 3. Additionally, 21% were WFNS grade 4, and 33% were grade 5 in Fisher’s group 3, and the ratio was significantly higher than that in other groups with 6.2% of grade 4 and 7.2% of grade 5. Since DIND was defined as the new neurological deficit, its incidence in extremely severe cases might not accurately evaluate the relationship between hematoma volume and DIND, as reported in some studies,29-30 even after excluding the data of patients with mortality at more than 5 days after onset.

Table 3 Factors related significantly to delayed ischemic neurological deficit based on multivariate analysis

| Risk factor                        | Odds ratio | 95% confidence interval | P-value |
|------------------------------------|------------|-------------------------|---------|
| Female sex                         | 1.39       | 0.90-2.19                | 0.137   |
| Diabetes mellitus                  | 0.43       | 0.13-1.09                | 0.080   |
| Aneurysm site at the ICA           | 1.59       | 1.04-2.40                | 0.031*  |
| Cilostazol                         | 0.52       | 0.29-0.87                | 0.013*  |
| Hemorrhagic complications           | 1.76       | 1.06-8.85                | 0.031*  |
| Radical operation type of surgical clipping | 1.63       | 1.09-2.44                | 0.017*  |

*Significant groupwise difference.
ICA, internal carotid artery.

Table 4 Factors related significantly to delayed ischemic neurological deficit in the IVR group

| Risk factor                        | Univariate analysis | Multivariate analysis |
|------------------------------------|---------------------|-----------------------|
|                                    | P-value             | Odds ratio            | 95% confidence interval | P-value |
| Female sex                         | 0.023               | 1.94                  | 0.95-4.29                | 0.070   |
| Size (>7 mm)                       | 0.057               | 0.58                  | 0.29-1.11                | 0.101   |
| Cilostazol                         | 0.034               | 0.46                  | 0.19-0.98                | 0.044*  |
| Hemorrhagic complications           | 0.031               | 1.80                  | 0.86-3.59                | 0.114   |

*Significant groupwise difference.
IVR, endovascular coil embolization.
The results of several meta-analysis studies have highlighted the potential effectiveness of cilostazol for DIND prevention. Cilostazol is a selective inhibitor of phosphodiesterase-3 and has an effect on microcirculatory vasodilatation, mediated by both cyclic adenosine monophosphate and upregulation of endothelial NO synthesis. Although this effect remained controversial, the recent meta-analysis demonstrated the possibility to prevent severe angiographic and symptomatic vasospasm, new cerebral infarction, and poor outcomes. The results are consistent with those of our study to reduce the incidence of DIND by approximately 50% in patients administered with cilostazol. Based on the Japanese Guidelines for the Management of Stroke 2015 (compatible with the 2017 revision), future large-scale comparative studies are needed to provide evidence-based support for cilostazol as an acceptable method to prevent DIND. This result was similar in patients who were treated with EC.

Drug administration
The AHA/ASA guidelines strongly recommend oral administration of nimodipine, which has not been approved in Japan. Moreover, although the Japanese Guidelines for the Management of Stroke strongly recommends intravenous administration of fasudil hydrochloride and ozagrel sodium, large-scale controlled trials of these drugs are needed. We could not evaluate drug efficacy due to insufficient numbers of patients meeting inclusion criteria. At our institute, besides statin, cilostazol and EPA have routinely been used since 2010, despite no clear evidence of statin and EPA and other drugs; nevertheless, the present study failed to show preventive effects of those against DIND.

Limitations
Our study has some limitations. First, this was a single-center retrospective study, and the comparisons were biased. The selection of various treatments was according to the physician’s discretion, which may have influenced the outcome of this analysis. Aneurysm location, age, and severity of SAH may also be confounding factors, as they greatly affect the treatment strategy; larger studies are needed to remove these effects. Additionally, in our series, WFNS grades 4 and 5 were 19.3% and 29.9%, respectively, and approximately 90% of the cases were classified into Fisher’s group 3, which may indicate that we were analyzing more severe cases than those in the general population. Future multicenter comparative studies to elucidate the efficacy of drugs with potential preventive action against DIND are needed.

Conclusions
ICA aneurysm was a risk factor for DIND after radical treatment for SAH in patients with intracranial aneurysms who underwent treatment at our institute. EC and oral cilostazol were factors for DIND prevention. This result was similar in patients who were treated with EC. Oral cilostazol showed potential in DIND prevention, and aggressive administration of cilostazol was the preferred treatment approach. In terms of DIND, surgeons should consider EC to be an appropriate modality.

Ethical Approval
All procedures were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study has received approval from the Institutional Review Boards of our institute, and the patient provided consent for publication.

Funding
No funding was received for this research.

Conflicts of Interest Disclosure
H. Imamura received Speakers’ Bureau/Honoraria from Medtronic Co. N. Sakai received Speakers’ Bureau/Honoraria from JIMRO Co., Johnson & Johnson K.K., Medtronic Co., Penumbra Co., and Stryker Japan K.K., and research funding from the Japanese Ministry of Health, Labour and Welfare and Terumo Co. Other authors have no conflicts of interest that are related to this manuscript.

References
1) Hughes JD, Bond KM, Mekary RA, et al.: Estimating the global incidence of aneurysmal subarachnoid hemorrhage: a systematic review for central nervous system vascular lesions and meta-analysis of ruptured aneurysms. World Neurosurg 115: 430-447, 2018
2) Nieuwkamp DJ, Setz LE, Algra A, Linn FH, De Rooij NK, Rinkel GJ: Changes in case fatality of aneurysmal subarachnoid hemorrhage over time, according to age, sex, and region: a meta-analysis. Lancet Neurol 8: 635-642, 2009
3) Goto O, Tamura A, Kirino T, Sano K, Nihei H, Manaka S: Vasospasm and its outcome after early surgery for ruptured cerebral aneurysms: relationship with the clinical grade based on the Glasgow Coma Scale. No Shinkei Geka 21: 221-226, 1993
4) Roos YB, de Haan RJ, Beenen LF, Groen RJ, Albrecht KW, Vermeulen M: Complications and outcome in patients with aneurysmal subarachnoid hemorrhage: a prospective hospital based cohort study in the Netherlands. J Neurol Neurosurg Psychiatry 68: 337-341, 2000
5) Imamura H, Sakai N, Sakai C, Fujiwaka T, Ishii A: Endovascular treatment of aneurysmal subarachnoid hemorrhage in Japanese Registry of Neuroendovascular Therapy (JR-NET) I and 2. Neurol Med Chir (Tokyo) 54: 81-90, 2014
6) Kassell NF, Torner JC, Haley EC Jr, Jane JA, Adams HP, Kongable

Neurol Med Chir (Tokyo) 62, May, 2022
Coiling and Cilostazol Reduce Symptomatic Vasospasm

229

GL: The International Cooperative Study on the Timing of Aneu-
rysms Surgery. Part I: overall management results. J Neurosurg 73: 18-36, 1990

7) Harrod CG, Bendok BR, Batjer HH: Prediction of cerebral vasospasm in patients presenting with aneurysmal subarachnoid hemorrhage: a review. Neurosurgery 56: 633-654, 2005

8) Imamura H, Sakai N, Satow T, Iihara K: Endovascular treatment for vasospasm after aneurysmal subarachnoid hemorrhage based on data of JR-NEST3. Neurol Med Chir (Tokyo) 58: 495-502, 2018

9) Molyneux A, Kerr R, Stratton I, et al: International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneu-
rysms: a randomized trial. Lancet 360: 1267-1274, 2002

10) Stroke Guidelines Committee of the Japan Stroke Society: Japa-
nese guidelines for the management of stroke 2015, Tokyo, Kyowa Kimex, 2015

11) Connolly ES Jr, Rabinstein AA, Carhuapoma JR, et al: Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 43: 1711-1737, 2012

12) Dankbaar JW, Slooter AJ, Rinkel GJ, et al: Effect of different components of triple-H therapy on cerebral perfusion in patients with aneurysmal subarachnoid haemorrhage: a systematic review. Crit Care 14: R23, 2010

13) Rinkel GJ, Feigin VL, Algra A, van Gijn J: Circulatory volume ex-
pansion therapy for aneurysmal subarachnoid haemorrhage. Co-
chrane Database Syst Rev 4: CD000483, 2004

14) Hadeishi H, Mizuno M, Suzuki A, Yasui N: Hyperdynamic therapy for cerebral vasospasm. Neurol Med Chir (Tokyo) 30: 317-323, 1990

15) Jun P, Ko NU, English JD, et al: Endovascular treatment of medi-
cally refractory cerebral vasospasm following aneurysmal suba-
rahnoid hemorrhage. AJNR Am J Neuroradiol 31: 1911-1916, 2010

16) Tachibana E, Harada T, Shibuya M, et al: Intra-arterial infusion of fasudil hydrochloride for treating vasospasm following sub-
rachnoid haemorrhage. Acta Neurochir (Wien) 141: 13-19, 1999

17) McDougall CG, Spetzler RF, Zabramski JM, et al: The Barrow ruptured aneurysm trial. J Neurosurg 116: 135-144, 2012

18) Alaraj A, Wallace A, Mander N, Aletich V, Charbel FT, Amin-
Hanjani S: Outcome following symptomatic cerebral vasospasm on presentation in unruptured intracranial aneurysms: a systematic review and meta-analysis. Neurosurg Rev 30: 22-30, 2007

19) de Oliveira JG, Beck J, Ulrich C, Rathert J, Raabe A, Seifert V: Comparison between clipping and coiling on the incidence of cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. Neurosurg Rev 30: 22-30, 2007

20) Dumont AS, Crowley RW, Monteith SJ, et al: Endovascular treat-
ment of neurosurgical clipping of ruptured intracranial aneu-
rysms: effect on angiographic vasospasm, delayed ischemic neu-
rological deficit, cerebral infarction, and clinical outcome. Stroke 41: 2519-2524, 2010

21) Hoh BL, Topcuoglu MA, Singhal AB, et al: Effect of clipping, cra-
niotomy, or intravascular coiling on cerebral vasospasm and pa-
tient outcome after aneurysmal subarachnoid hemorrhage. Neu-
rosurgery 55: 779-786, 2004

22) Jones J, Sayre J, Chang R, et al: Cerebral vasospasm patterns fol-
lowing aneurysmal subarachnoid hemorrhage: an angiographic study comparing coils with clips. J Neurointerv Surg 7: 803-807, 2015

23) Rabinstein AA, Pichelmann MA, Friedman JA, et al: Sympto-
matic vasospasm and outcomes following aneurysmal subarach-
noid hemorrhage: a comparison between surgical repair and en-
dovascular coil occlusion. J Neurosurg 98: 319-325, 2003

24) Suzuki H, Taki W: Prospective Registry of Subarachnoid Aneu-
rysms Treatment (PRESAT) group: effect of aneurysm treatment modalities on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Acta Neurochir Suppl 115: 99-105, 2013

25) Weir B, Macdonald RL, Stoodley M: Etiology of cerebral vasosp-
asm. Acta Neurochir Suppl 72: 27-46, 1999

26) Zaidat OO, Ionita CC, Hussain SI, Alexander MJ, Friedman AH, Graffagnino C: Impact of ruptured cerebral aneurysm coiling and clipping on the incidence of cerebral vasospasm and clinical outcome. J Neuroimaging 19: 144-149, 2009

27) Matsushige T, Sakamoto S, Ishii D, et al: Safety and efficacy of a new outreach distal access catheter, TACTICS, for coil emboliza-
tion of unruptured intracranial aneurysms. Interv Neuroradiol 24: 482-488, 2018

28) Spiotta AM, Miranpuri A, Hawk H, Chaudry MI, Turk AS, Turner RD: Balloon remodeling for aneurysm coil embolization with the coaxial lumen Scepter C balloon catheter: initial experience at a high volume center. J Neurinterv Surg 5: 582-585, 2013

29) Taqi MA, Quadri SA, Puri AS, et al: A prospective multicenter trial of the TransForm occlusion balloon catheter: trial design and results. Interv Neurol 7: 53-64, 2018

30) Abba AA, Wilson DA, Williamson RW, et al: The relationship be-
tween ruptured aneurysm location, subarachnoid hemorrhage clot thickness, and incidence of radiographic or symptomatic va-
sospasm in patients enrolled in a prospective randomized con-
trolled trial. J Neurosurg 120: 391-397, 2014

31) Frontera JA, Claassen J, Schmidt JM, et al: Prediction of sympto-
matic vasospasm after subarachnoid hemorrhage: the modified fisher scale. Neurosurgery 59: 21-27, 2006

32) Hurth H, Steiner J, Birkenhauer U, et al: Relationship of the vas-
cular territory affected by delayed cerebral ischemia and the loca-
tion of the ruptured aneurysm in patients with aneurysmal subarachnoid hemorrhage. Neurosurg Rev 2021. doi: 10.1007/s10143-021-01522-4. Online ahead of print

33) Darkwah Oppong M, Iannaccone A, Gembruch O, et al: Vasospasm-related complications after subarachnoid hemor-
rhage: the role of patients’ age and sex. Acta Neurochir (Wien) 160: 1393-1400, 2018

34) Jung SW, Lee CY, Yim MB: The relationship between subarach-
noid hemorrhage volume and development of cerebral vaso-
sospasm. J Cerebrovasc Endovasc Neurosurg 14: 186-191, 2012

35) Boulouis G, Labeyrie MA, Raymond J, et al: Treatment of cere-
bral vasospasm following aneurysmal subarachnoid haemorrh-
age: a systematic review and meta-analysis. Eur Radiol 27: 3333-3342, 2017

36) Qureshi A, Ishfaq A, Ishfaq MF, et al: Therapeutic benefit of cilostazol in patients with aneurysmal subarachnoid hemorrhage: a meta-analysis of randomized and nonrandomized studies. J Vasc Interv Neurol 10: 33-40, 2018

37) Saber H, Desai A, Palla M, Mohamed Wm Seraji-Bozorgzad N, Ibrahim M: Efficacy of cilostazol in prevention of delayed cere-
bral ischemia after aneurysmal subarachnoid hemorrhage: a meta-analysis. J Stroke Cerebrovasc Dis 27: 2979-2985, 2018

38) Ito H, Hashimoto A, Matsumoto Y, et al: Cilostazol, a phos-
phodiesterase inhibitor, attenuates photothermobic focal ischemic brain injury in hypertensive rats. J Cereb Blood Flow Metab 30: 343-351, 2010

39) Bohara S, Garg K, Singh Rajpal PM, et al: Role of cilostazol in prevention of vasospasm after aneurysmal subarachnoid

Neurol Med Chir (Tokyo) 62, May, 2022
hemorrhage—a systematic review, meta-analysis, and trial sequential analysis. *World Neurosurg* 150: 161-170, 2021

40) Dorhout Mess SM, van den Bergh WM, Algra A, Rinkel GJ: Anti-platelet therapy for aneurysmal subarachnoid haemorrhage. *Cochrane Database Syst Rev* 4: CD006184, 2007

41) Suzuki Y, Shibuya M, Satoh S, Sugimoto T, Takakura K: A post-marketing surveillance study of fasudil treatment after aneurysmal subarachnoid hemorrhage. *Surg Neurol* 68: 126-131, 2007

42) Tokiyoshi K, Ohnishi T, Nii Y: Efficacy and toxicity of thromboxane synthetase inhibitor for cerebral vasospasm after subarachnoid hemorrhage. *Surg Neurol* 36: 112-118, 1991

43) Tseng MY, Hutchinson PJ, Czosnyka M, Richards H, Pickard JD, Kirkpatrick PJ: Effects of acute pravastatin treatment on intensity of rescue therapy, length of inpatient stay, and 6-month outcome in patients after aneurysmal subarachnoid hemorrhage. *Stroke* 38: 1545-1550, 2007

44) Yoneda H, Shirao S, Nakagawara J, Ogasawara K, Tominaga T, Suzuki M: A prospective, multicenter, randomized study of the efficacy of eicosapentaenoic acid for cerebral vasospasm: the EVAS study. *World Neurosurg* 81: 309-315, 2014

Corresponding author: Hirotoshi Imamura, MD, PhD
Department of Neurosurgery, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan.

*e-mail*: i-hiro@zg7.so-net.ne.jp